References
Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011; 25: 1877–1881.
Zwick C, Hartmann F, Zeynalova S, Poschel V, Nickenig C, Reiser M et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 2011; 22: 1872–1877.
Pettengell R, Johnson HE, Lugtenburg PJ, Silvestre AS, Duhrsen U, Rossi FG et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 2012; 20: 647–652.
Chanan-Khan AA, Cheson BD . Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544–1552.
Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713–4720.
Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 2009; 27: 5404–5409.
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650–4657.
Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84: 553–559.
Fowler N, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M et al. Lenalidomide plus rituximab a highly effective and well-tolerated biologic therapy in untreated indolent B-cell non-hodgkin lymphoma. Ann Oncol. 2011; 22 (Supp 4): iv129.
Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d’etude des lymphomes de l’adulte. J Clin Oncol 2010; 28: 822–829.
Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732.
Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42–51.
Acknowledgements
This trial was supported by a grant from the French Ministry of Health (PHRC 2009 13-03). Celgene Corporation financially supported the trial and provided the study drug. We thank the staff of the GELA-Recherche Clinique, and especially Yvain Robreau, for the management of the trial.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Tilly, Dr Morschhauser, Dr Salles, Dr Haioun and Dr Coiffier received grant support from Celgene. Dr Tilly, Dr Morschhauser, Dr Salles, Dr Haioun and Dr Coiffier received payment for lectures from Celgene. Dr Tilly, Dr Morschhauser, Dr Salles and Dr Coiffier have served on advisory boards of Celgene. Dr Casasnovas, Dr Feugier, Dr Molina, Dr Jardin and Dr Terriou declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Tilly, H., Morschhauser, F., Salles, G. et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 27, 252–255 (2013). https://doi.org/10.1038/leu.2012.172
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.172
- Springer Nature Limited
This article is cited by
-
IMiDs New and Old
Current Hematologic Malignancy Reports (2019)
-
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
Molecular Cancer (2015)
-
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
Journal of Medical Case Reports (2014)
-
The tumour microenvironment in B cell lymphomas
Nature Reviews Cancer (2014)
-
Accelerated therapeutic progress in diffuse large B cell lymphoma
Annals of Hematology (2014)